<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089357</url>
  </required_header>
  <id_info>
    <org_study_id>05PF2009</org_study_id>
    <nct_id>NCT05089357</nct_id>
  </id_info>
  <brief_title>Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin</brief_title>
  <official_title>A Prospective, Non-interventional Study to Collect Subject and Physician Satisfaction During Long Term Treatment of Glabellar Lines With Dysport® in Subjects of Chinese Origin in Real Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Q-Med AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Q-Med AB</source>
  <brief_summary>
    <textblock>
      This is a prospective, longitudinal, non-interventional, multi-center study to collect&#xD;
      subject and physician satisfaction, and treatment experience with Dysport in real clinical&#xD;
      practice in subjects of Chinese origin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 250 subjects are planned to be included in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subject satisfaction assessed by Subject Satisfaction Questionnaire</measure>
    <time_frame>3 weeks after 3rd injection</time_frame>
    <description>At Visit 6 (i.e., three weeks, after the 3rd injection) subjects will be asked &quot;What is your overall satisfaction after three treatment cycles?&quot;&#xD;
Response options:&#xD;
Very Satisfied Satisfied Dissatisfied Very Dissatisfied The primary endpoint will evaluate the proportion of subjects in each response category</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Glabellar Lines</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female adult subjects up to 65 years of age with moderate to severe glabellar&#xD;
        lines (GL)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female up to 65 years of age, and of Chinese origin.&#xD;
&#xD;
          -  Moderate (grade 2) or severe (grade 3) glabellar lines at max frown.&#xD;
&#xD;
          -  Prior to and independent of study, subject is seeking long term treatment of their&#xD;
             glabellar lines.&#xD;
&#xD;
          -  Prior to and independent of the study participation, physician intended to treat the&#xD;
             subject with Dysport.&#xD;
&#xD;
          -  Time and ability to complete the study and comply with instructions.&#xD;
&#xD;
          -  Understands the study requirements and signed the informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitive to Dysport or its excipients.&#xD;
&#xD;
          -  Presence of contraindications to Dysport treatment as specified in the approved&#xD;
             leaflet in China.&#xD;
&#xD;
          -  Subject is at risk for precautions, warnings, and/or contraindications to Dysport as&#xD;
             specified in the approved leaflet in China.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weiming Song</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hangzhou Yanshuyuerong medical cosmetology clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Chen</last_name>
    <phone>+86 21 2315 9790</phone>
    <email>nicole.chen@galderma.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

